| Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies (NCT00473551) | M.D. Anderson Cancer Center | 2007-05-01 |
| Treatment of Myeloma in Patients <= 65 Years Old With Response >= 50% After HSC Autotransplant by Allogenic Transplant Genoidentical or Phenoidentical After Reduced Intensity Conditioning (NCT00466674) | Hospices Civils de Lyon | 2007-01-01 |
| Bevacizumab and Bortezomib in Patients With Advanced Malignancy (NCT00428545) | M.D. Anderson Cancer Center | 2007-01-01 |
| Adoptive Cellular Immunotherapy Following Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma (NCT00439465) | Dartmouth-Hitchcock Medical Center | 2007-01-01 |
| Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies (NCT00410982) | M.D. Anderson Cancer Center | 2006-12-01 |
| Long-Term Follow Up Study for AMD3100 Patients (NCT00476294) | M.D. Anderson Cancer Center | 2006-10-01 |
| Maintenance Therapy Using Lenalidomide in Myeloma (NCT00430365) | University Hospital, Toulouse | 2006-06-01 |
| Efficacy and Safety of Oral CEP-701 for the Treatment of Patients With Advanced Multiple Myeloma (NCT00242827) | Cephalon | 2006-04-01 |
| Total Body Irradiation With Fludarabine Followed by Combined Umbilical Cord Blood (UCB) Transplants (NCT00606437) | Duke University | 2005-09-01 |
| Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT) (NCT00361140) | H. Lee Moffitt Cancer Center and Research Institute | 2005-08-01 |
| Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath (NCT00578942) | David Rizzieri, MD | 2005-05-01 |
| Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies (NCT00990717) | University Health Network, Toronto | 2005-03-01 |
| Minor Histocompatibility Vaccination After Allogeneic Stem Cell Transplantation for Advanced Hematologic Malignancies (NCT00943293) | University of Chicago | 2003-05-01 |
| TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma (NCT01039025) | M.D. Anderson Cancer Center | 2002-02-18 |
| Targeted Radiotherapy in HSCT for Poor Risk Haematological Malignancy (NCT01521611) | University Hospital Southampton NHS Foundation Trust | 2002-01-01 |
| Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support (NCT00070616) | Swedish Orphan Biovitrum | 2001-12-01 |
| Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients (NCT00195533) | Wyeth is now a wholly owned subsidiary of Pfizer | 2001-07-01 |
| Vincristine, DOXIL (Doxorubicin HCl Liposome Injection) and Dexamethasone vs. Vincristine, Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NCT00344422) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2000-10-01 |
| Bone Marrow Transplantation With Specially Treated Bone Marrow in Treating Patients With Hematologic Cancer That Have Not Responded to Previous Therapy (NCT00005988) | Dana-Farber Cancer Institute | 2000-02-01 |
| Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer (NCT00001582) | National Cancer Institute (NCI) | 1997-06-07 |
| Atorvastatin in Myeloma (NCT00164086) | Bayside Health | |